Cipla Ltd CIPLA

The role will focus on identifying new opportunities and strengthening existing customer relationships to accelerate Ritedose’s continued growthCOLUMBIA, S.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation (Ritedose), the largest contract development and manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit-dose solutions for the ophthalmic and respiratory markets, today announced the appointment of Carolyn Berg as th

Cipla secured exclusive U.S. commercialization rights to Qilu's proposed biosimilar ahead of Keytruda's expected 2028 patent expiration.

Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087) (NSE: CIPLA) today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States

Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"), today announced that Cipla Limited has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths—100/50 mcg, 250/50 mcg, and 500/50 mcg.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Generic Drug Market size & share revenue was valued at approximately USD 491.35 Billion in 2024 and is expected to reach USD 519.11 Billion in 2025 and is expected to reach around USD 926.54 Billion by 2034, at a CAGR of 6.55% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Alkem Laboratories Limited, T

Cipla Ltd (BOM:500087) reports robust revenue growth in India and North America, while focusing on AI-driven efficiency and a promising product pipeline.

The pharmaceutical giant just extended the lifespan of one of its top drugs.

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd, resolving patent infringement litigation regarding VYNDAMAX (tafamidis). These agreements effectively extend Pfizer’s US patent protection for the transthyretin-mediated amyloidosis (ATTR-CM) treatment […]

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Cipla Limited (BSE: 500087) (NSE: CIPLA-EQ) (hereafter referred to as 'Cipla') and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as 'Cipla'), today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation from the United States Food and Drug Administration (USFDA). It is the first AB–rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline.

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087) (NSE: CIPLA) (hereafter referred to as "Cipla") today announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nintedanib Capsules, 100 mg and 150 mg, indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State